Analysts’ Weekly Ratings Updates for Fortrea (FTRE)

Several brokerages have updated their recommendations and price targets on shares of Fortrea (NASDAQ: FTRE) in the last few weeks:

• 5/12/2026 – Fortrea had its price target raised by Mizuho from $11.00 to $13.00. They now have a “neutral” rating on the stock.
• 5/7/2026 – Fortrea had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $14.00 price target on the stock.
• 5/6/2026 – Fortrea was given a new $19.00 price target by Truist Financial Corporation.
• 5/6/2026 – Fortrea had its “buy” rating reaffirmed by TD Cowen.
• 5/6/2026 – Fortrea had its price target raised by Citigroup Inc. from $16.00 to $20.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Fortrea was given a new $20.00 price target by Robert W. Baird.
• 5/6/2026 – Fortrea had its price target raised by Barclays PLC from $11.00 to $16.00. They now have an “equal weight” rating on the stock.
• 4/21/2026 – Fortrea had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/14/2026 – Fortrea had its price target lowered by Barclays PLC from $12.00 to $11.00. They now have an “equal weight” rating on the stock.

Insider Activity at Fortrea

In other news, CFO Jill G. Mcconnell sold 5,061 shares of Fortrea stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $9.07, for a total value of $45,903.27. Following the completion of the transaction, the chief financial officer owned 69,796 shares in the company, valued at approximately $633,049.72. This trade represents a 6.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 8,792 shares of company stock valued at $80,014. 0.38% of the stock is currently owned by company insiders.

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.